347 related articles for article (PubMed ID: 27561266)
1. High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.
Jamani R; Lee EK; Berry SR; Saluja R; DeAngelis C; Giotis A; Emmenegger U
Eur J Clin Pharmacol; 2016 Nov; 72(11):1391-1399. PubMed ID: 27561266
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.
Benoist GE; van Oort IM; Smeenk S; Javad A; Somford DM; Burger DM; Mehra N; van Erp NP
Br J Clin Pharmacol; 2018 Jan; 84(1):122-129. PubMed ID: 28881501
[TBL] [Abstract][Full Text] [Related]
3. Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.
Bonnet C; Boudou-Rouquette P; Azoulay-Rutman E; Huillard O; Golmard JL; Carton E; Noé G; Vidal M; Orvoen G; Chah Wakilian A; Villeminey C; Blanchet B; Alexandre J; Goldwasser F; Thomas-Schoemann A
Cancer Chemother Pharmacol; 2017 May; 79(5):1051-1055. PubMed ID: 28361167
[TBL] [Abstract][Full Text] [Related]
4. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
Houédé N; Beuzeboc P; Gourgou S; Tosi D; Moise L; Gravis G; Delva R; Fléchon A; Latorzeff I; Ferrero JM; Oudard S; Tartas S; Laguerre B; Topart D; Roubaud G; Agherbi H; Rebillard X; Azria D
BMC Cancer; 2015 Apr; 15():222. PubMed ID: 25884302
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
[TBL] [Abstract][Full Text] [Related]
7. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B
Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction.
Cindolo L; Natoli C; De Nunzio C; De Tursi M; Valeriani M; Giacinti S; Micali S; Rizzo M; Bianchi G; Martorana E; Scarcia M; Ludovico GM; Bove P; Laudisi A; Selvaggio O; Carrieri G; Bada M; Castellan P; Topazio L; Boccasile S; Ditonno P; Chiodini P; Schips L
Clin Genitourin Cancer; 2017 Oct; 15(5):520-525. PubMed ID: 28478884
[TBL] [Abstract][Full Text] [Related]
9. Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors.
Procopio G; Grassi P; Testa I; Verzoni E; Torri V; Salvioni R; Valdagni R; de Braud F
Am J Clin Oncol; 2015 Oct; 38(5):479-82. PubMed ID: 24064757
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation.
Prati V; Ruatta F; Aversa C; Gernone A; Galizia D; Bonzano A; Torino S; Nuzzolese I; Marandino L; Aglietta M; Ortega C
Future Oncol; 2018 Feb; 14(5):443-448. PubMed ID: 29318908
[TBL] [Abstract][Full Text] [Related]
11. Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer.
Beardo-Villar P; Ledo-Cepero MJ; Gavira-Moreno R; Soto-Delgado M; Soto-Villalba J; Alvarez-Ossorio JL; Juárez-Soto A
Actas Urol Esp; 2014 Jun; 38(5):339-45. PubMed ID: 24480574
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis.
Koninckx M; Marco JL; Pérez I; Faus MT; Alcolea V; Gómez F
Clin Transl Oncol; 2019 Mar; 21(3):314-323. PubMed ID: 30022386
[TBL] [Abstract][Full Text] [Related]
13. Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden.
Svensson J; Andersson E; Persson U; Edekling T; Ovanfors A; Ahlgren G
Scand J Urol; 2016 Aug; 50(4):286-91. PubMed ID: 27109827
[TBL] [Abstract][Full Text] [Related]
14. Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.
Binder M; Zhang BY; Hillman DW; Kohli R; Kohli T; Lee A; Kohli M
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409606
[TBL] [Abstract][Full Text] [Related]
15. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Massoudi M; Balk M; Yang H; Bui CN; Pandya BJ; Guo J; Song Y; Wu EQ; Brown B; Barlev A; Flanders S
J Med Econ; 2017 Feb; 20(2):121-128. PubMed ID: 27570999
[TBL] [Abstract][Full Text] [Related]
16. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
[TBL] [Abstract][Full Text] [Related]
17. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E
Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222
[TBL] [Abstract][Full Text] [Related]
18. Abiraterone acetate in the treatment of prostate cancer.
Thakur A; Roy A; Ghosh A; Chhabra M; Banerjee S
Biomed Pharmacother; 2018 May; 101():211-218. PubMed ID: 29494958
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.
Han CS; Patel R; Kim IY
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418
[TBL] [Abstract][Full Text] [Related]
20. How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer.
Wang Y; Dason S; Shayegan B
Can J Urol; 2016 Aug; 23(4):8388-94. PubMed ID: 27544566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]